Edward Tenthoff
Stock Analyst at Piper Sandler
(3.08)
# 1,331
Out of 5,042 analysts
181
Total ratings
43.68%
Success rate
0.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $449 → $489 | $456.04 | +7.23% | 15 | Oct 31, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $13 → $16 | $8.74 | +83.07% | 5 | Oct 30, 2025 | |
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $15 → $12 | $5.80 | +106.90% | 1 | Oct 9, 2025 | |
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $4.16 | +188.46% | 2 | Sep 15, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $12.60 | +19.05% | 5 | Jul 15, 2025 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $5 | $2.35 | +112.77% | 1 | Jul 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $63.99 | +64.09% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $1.12 | +78.57% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $1.36 | +414.71% | 1 | Jun 3, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $10.14 | +38.07% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $2 | $0.58 | +242.99% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $22.58 | +112.58% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $16.66 | +44.06% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $32.40 | +140.74% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $14.69 | +104.22% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $42.39 | +6.16% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $27.16 | +154.05% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $10.18 | +538.51% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.51 | +437.63% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.55 | +1,190.32% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.36 | +120.59% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.77 | +290.83% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $12.85 | +24.51% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.35 | +344.44% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.92 | +160.42% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $61.84 | -9.44% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $30.21 | +720.92% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $4.04 | +2,127.72% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $16.10 | +1,018.01% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.78 | +147.54% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $8.07 | +358.49% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.55 | +42,012,803.23% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $818.50 | -56.75% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.69 | +7,888.17% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $425.57 | -24.10% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $38.67 | -6.90% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $0.99 | +2,431.13% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $1.38 | +10,769.57% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.55 | +250,809.09% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $651.80 | - | 11 | Feb 13, 2017 |
Alnylam Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $456.04
Upside: +7.23%
Fulcrum Therapeutics
Oct 30, 2025
Reiterates: Overweight
Price Target: $13 → $16
Current: $8.74
Upside: +83.07%
Karyopharm Therapeutics
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $5.80
Upside: +106.90%
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $4.16
Upside: +188.46%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $12.60
Upside: +19.05%
Inovio Pharmaceuticals
Jul 9, 2025
Initiates: Overweight
Price Target: $5
Current: $2.35
Upside: +112.77%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $63.99
Upside: +64.09%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $1.12
Upside: +78.57%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.36
Upside: +414.71%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $10.14
Upside: +38.07%
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.58
Upside: +242.99%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $22.58
Upside: +112.58%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $16.66
Upside: +44.06%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $32.40
Upside: +140.74%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $14.69
Upside: +104.22%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $42.39
Upside: +6.16%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $27.16
Upside: +154.05%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $10.18
Upside: +538.51%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $6.51
Upside: +437.63%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.55
Upside: +1,190.32%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.36
Upside: +120.59%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.77
Upside: +290.83%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $12.85
Upside: +24.51%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.35
Upside: +344.44%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.92
Upside: +160.42%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $61.84
Upside: -9.44%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $30.21
Upside: +720.92%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $4.04
Upside: +2,127.72%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $16.10
Upside: +1,018.01%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.78
Upside: +147.54%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $8.07
Upside: +358.49%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.55
Upside: +42,012,803.23%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $818.50
Upside: -56.75%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.69
Upside: +7,888.17%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $425.57
Upside: -24.10%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $38.67
Upside: -6.90%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $0.99
Upside: +2,431.13%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $1.38
Upside: +10,769.57%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.55
Upside: +250,809.09%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $651.80
Upside: -